Skip to content

Study · Not a test of the peptide alone · 2001

4 results

E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.

Anderson SM, Wideman L, Patrie JT, Weltman A, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism1 Dec 2001Cited by 31 (Europe PMC)

PMID11739462 (opens in a new tab)DOI10.1210/jcem.86.12.8076 (opens in a new tab)PepBankPUB-11739462
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women without exogenous GH autofeedback, E2 replacement enhanced the stimulatory effect of GHRP‑2 on incremental peak GH release by 1.58-fold.

    In plain wordsIn postmenopausal women, estradiol made the GH release caused by GHRP‑2 about 1.58 times larger than placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRP-2-stimulated incremental peak GH after E2
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    fold change in peak GH
    1.58 fold
    E2 versus placebo

    Source sentences

    Summary
    In the absence of exogenously imposed GH autofeedback, E2 replacement enhanced the stimulatory effect of GHRP-2 on incremental peak GH release by 1.58-fold [95% confidence interval, 1.2- to 2.1-fold] (P = 0.0034)
    1 context sentence
    Summary · context
    To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17 beta-E2 orally twice daily for 6-23 d].

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In the E2-deficient state, a bolus GH infusion inhibited the GHRP-induced incremental peak GH response by 54%.

    In plain wordsIn postmenopausal women not given estradiol, a GH infusion reduced the GH response to a GHRP by 54% compared with saline.

    Peptide
    GHRP-2
    Outcome
    DecreaseGHRP-induced incremental peak GH after a GH infusion in the E2-deficient state
    Study

    n = 9

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    inhibition of peak GH response
    54%
    GHRP-induced, versus saline

    Source sentences

    Summary
    In the E2-deficient state, bolus GH infusion significantly inhibited subsequent spontaneous, GHRH-, and GHRP-induced incremental peak GH responses by, respectively, 33% (1-55%; P = 0.044 vs. saline), 79% (68-86%; P < 0.0001), and 54% (32-69%; P = 0.0002).
    1 context sentence
    Summary · context
    To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17 beta-E2 orally twice daily for 6-23 d].

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In the presence of GH autoinhibition, E2 replenishment augmented the GHRP‑2-stimulated incremental peak GH response by 1.7-fold.

    In plain wordsIn postmenopausal women, estradiol increased the GH response to GHRP‑2 by 1.7 times, even after a GH infusion had suppressed it.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRP-2-stimulated incremental peak GH under GH autoinhibition after E2
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    fold change in peak GH
    1.7 fold
    E2 versus placebo

    Source sentences

    Summary
    In contrast, E2 replenishment augmented the GHRP-2-stimulated incremental peak GH response in the face of GH autoinhibition by 1.7-fold (1.2- to 2.5-fold; P = 0.009).
    1 context sentence
    Summary · context
    To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17 beta-E2 orally twice daily for 6-23 d].

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    E2 raised GH-repressed, GHRP‑2-stimulated GH secretory pulse mass by 1.5-fold, but the change was not significant (P = 0.078).

    In plain wordsEstradiol raised GHRP‑2-stimulated GH pulse mass by 1.5-fold in postmenopausal women, but this change was not statistically significant.

    Peptide
    GHRP-2
    Outcome
    No significant changeGHRP-2-stimulated GH pulse mass under GH autoinhibition after E2
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    fold change in pulse mass
    1.5 fold
    E2 versus placebo

    Source sentences

    Summary
    Mechanistically, the latter effect of E2 mirrored its enhancement of GH-repressed/GHRP-2-stimulated GH secretory pulse mass, which rose by 1.5-fold (0.95- to 2.5-fold over placebo; P = 0.078).
    1 context sentence
    Summary · context
    To this end, we appraised GH autoinhibition in nine healthy postmenopausal volunteers during a prospective, randomly ordered supplementation with placebo vs. E [1 mg micronized 17 beta-E2 orally twice daily for 6-23 d].

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.